Search Within

Franziska Michor

Formats
  1. Journal Article (14)
  2. Meeting Abstract (9)
Groups
  1. GSK Faculty (5)
  2. Biostatistics Service (4)
  3. Department of Medicine (4)
  4. Epidemiology and Biostatistics (4)
  5. Hematologic Malignancies, Division of (4)
  6. Human Oncology and Pathogenesis Program (4)

More Groups

People
  1. Jasmine Foo (6)
  2. Camille Stephan-otto Attolini (4)
  3. Hiroshi Haeno (4)
  4. Mithat Gonen (3)
  5. Ross Levine (3)
  6. Adam Olshen (2)

More People

Years
  1. 2011 (1)
  2. 2010 (8)
  3. 2009 (8)
  4. 2008 (6)
Publications
  1. Cancer Research (4)
  2. Haematologica (3)
  3. PLoS Computational Biology (3)
  4. Blood (2)
  5. Journal of Theoretical Biology (2)
  6. Proceedings of the National Academy of Sciences of the United States of America (2)

More Publications

Publishers
  1. American Association for Cancer Research (4)
  2. Public Library of Science (4)
  3. Elsevier Inc. (3)
  4. Ferrata Storti Foundation (3)
  5. American Society of Hematology (2)
  6. National Academy of Sciences (2)

More Publishers

Results (23)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A computational approach to optimize dosing strategies for EGFR tyrosine kinase inhibitors in EGFR mutant lung adenocarcinoma
    Meeting Abstract

    Foo, J.; Chmielecki, J.; Pao, W.; Michor, F.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • EGFR T790M decreases growth potential of lung tumor cells with drug-sensitive EGFR mutant alleles in the absence of drug selection
    Meeting Abstract

    Chmielecki, J.; Foo, J.; Somwar, R.; Regales, L.; Vivanco, I.; Shen, R.; Michor, F.; Pao, W.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Towards the evolutionary trajectory leading to glioblastoma multiforme
    Meeting Abstract

    Attolini, C. S. O.; Beroukhim, R.; Mellinghoff, I.; Michor, F.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • A progenitor cell origin of myeloid malignancies
    Journal Article

    Haeno, H.; Levine, R. L.; Gilliland, D. G.; Michor, F.
    Proceedings of the National Academy of Sciences of the United States of America (2009)

    Fulltext@MSK | Save
  • Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies
    Journal Article

    Foo, J.; Michor, F.
    PLoS Computational Biology (2009)

    Fulltext@MSK | Save
  • Eradication of chronic myeloid leukemia stem cells: A novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib
    Journal Article

    Foo, J.; Drummond, M. W.; Clarkson, B.; Holyoake, T.; Michor, F.
    PLoS Computational Biology (2009)

    Fulltext@MSK | Save
  • Evolutionary theory of cancer
    Journal Article

    Attolini, C. S. O.; Michor, F.
    Annals of the New York Academy of Sciences (2009)

    Fulltext@MSK | Save
  • Molecular responses to dasatinib and nilotinib in patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Meeting Abstract

    Quintas-Cardama, A.; Kantarjian, H.; Michor, F.; Olshen, A.; Gonen, M.; Jones, D.; Rios, M. B.; O'Brien, S.; Cortes, J.
    Blood (2008)

    Fulltext@MSK | Save
  • Modelling BCR-ABL1 dynamics in patients with chronic myeloid leukemia in chronic phase (CML-CP) during frontline therapy with high-dose imatinib, nilotinib, or dasatinib
    Meeting Abstract

    Olshen, A.; Quintas-Cardama, A.; Kantarjian, H. M.; Gonen, M.; Michor, F.; Cortes, J.
    Blood (2008)

    Fulltext@MSK | Save
  • A one-mutation mathematical model can explain the age incidence of AML with mutated nucleophosmin (Npm1)
    Meeting Abstract

    Liso, A.; Castiglione, F.; Cappuccio, A.; Stracci, F.; Schlenk, R. F.; Amadori, S.; Thiede, C.; Schnittger, S.; Valk, P. J. M.; DoĢˆhner, K.; more...
    Haematologica (2008)

    Fulltext@MSK | Save